Nitsan Maayan-Rabinowich
Chief Executive Officer
Company profile
About Sight Diagnostics
Sight Diagnostics is pioneering a new generation of immune signatures by decoding live immune cells in action. The company combines exclusive proprietary data with cutting-edge artificial intelligence to deliver unprecedented clinical insights in the field of pathology and laboratory diagnostics. Sight's innovative approach focuses on analyzing immune cell behavior in real-time, enabling more accurate and comprehensive diagnostic capabilities. The company's technology platform represents a significant advancement in understanding immune system function and disease states. Led by CEO Nitsan Maayan-Rabinowich, CTO Ben Leshem PhD, and Chief Product & Clinical Officer Asi Cohen-Dotan PhD, Sight has gained recognition as a disruptor in the healthcare technology space. The company has been honored with multiple awards including recognition in CNBC's 2021 Disruptor 50 Companies list and Fast Company's 2021 World Changing Ideas Award. Sight's mission is to push the boundaries of innovation in diagnostic medicine, providing healthcare providers with advanced tools to better understand and monitor immune system health and function.
Company description Sight Diagnostics official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Sight Diagnostics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- immune cell analysis
- immune system disorders
Who it serves
- Clinical Laboratories
- Healthcare Providers
Deployment & integration
Deployment information is currently being developed.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Recognition as CNBC 2021 Disruptor 50 Company, Fast Company 2021 World Changing Ideas Award
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology.American journal of hematology · Oct 1, 2021
Evaluation of the Parasight Platform for Malaria Diagnosis.Journal of clinical microbiology · Mar 1, 2017
Computer Vision Malaria Diagnostic Systems-Progress and Prospects.Frontiers in public health · Jan 1, 2017
Computer-vision-based technology for fast, accurate and cost effective diagnosis of malaria.Malaria journal · Dec 30, 2015
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Sight OLOK190898 · 510k · Nov 1, 2019
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
LinkedIn
Ben Leshem
Chief Technology Officer
Asi Cohen-Dotan
Chief Product & Clinical Officer
06 · Company updates
Updates from Sight Diagnostics
Recent articles published on Sight Diagnostics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.